TD Private Client Wealth LLC Sells 4,004 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

TD Private Client Wealth LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,505 shares of the biopharmaceutical company’s stock after selling 4,004 shares during the quarter. TD Private Client Wealth LLC’s holdings in Gilead Sciences were worth $4,942,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GILD. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC increased its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last ninety days. 0.29% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $107.08 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The stock has a 50-day moving average of $103.68 and a 200-day moving average of $93.75. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. Gilead Sciences’s dividend payout ratio is 854.05%.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.